AgingResearch.NewsJoin free

Resveratrol + TA-65

Intervention

1 paper1 finding

C, W, M, H: cells, worms or flies, mice, humans. Dark: independent labs found the same change there. Light: one lab or one study. Outline: nothing yet.

Labs are independent when their papers share no last author and no institution.

Against: findings that point the other way from most findings on the same outcome.

On aging: the drug’s trials ARN judged to be about aging, of every trial that tests it for any use.

No results posted: trials that ended more than a year ago with no results on ClinicalTrials.gov and no paper in ARN’s record.

Company ties: findings with an author at a company, or from a paper whose competing-interests statement declares ties to one.

  • 1 lab in 1 country
  • Human trial1

Outcomes

1

LDL cholesterol

upin humans1

1 study

  1. Resveratrol + TA-65 increases LDL cholesterol in humans.

    “In group B, the study was interrupted at month 5 due to significant LDL-cholesterol increase, probably caused by the high-dose resveratrol.”

    Human trialGroup B; treatment interrupted at month 5resveratrol 350 mg bid + TA-65 100U5 months

    The proBNPage reduction (PBAR) trial-results of a randomized, double blind, placebo-controlled, pilot study to fine tune an NT-proBNP-based method to assess the effect of anti-aging treatments

    GeroScience8 Sep 2025

More on LDL cholesterol

Latest

Related